Shang, Xiaoying

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 617

Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment

Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., et al. (2020) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCytokine Signaling Pathways and Interactions

Cited by 213

Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression

Hsu, W.-H., LaBella, K. A., Lin, Y., Xu, P., Lee, R., Hsieh, C.-E., Yang, L., Zhou, A., Blecher, J. M., Wu, C.-J., et al. (2023) · Cancer Discovery

Cancer Cells and MetastasisAngiogenesis and VEGF in Cancer

Cited by 125

TERT activation targets DNA methylation and multiple aging hallmarks

Shim, H. S., Iaconelli, J., Shang, X., Li, J., Lan, Z. D., Jiang, S., Nutsch, K., Beyer, B. A., Lairson, L. L., Boutin, A. T., et al. (2024) · Cell

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 104